



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: February 4, 2011

To: Primary Clinical Research Associates

From: Sara Braun
Protocol Development Coordinator

Re: N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT)
Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Please note that with the activation of addenda 8 and 9, protocol N078D will re-open to accrual. Local IRB approval of Addenda 8 & 9 is required prior to further patient enrollment.

If you have any questions, please feel free to contact me.

Enclosure